Abrezekimab, a cutting-edge drug, is sparking substantial excitement within the healthcare community as a potential option for alleviating a range of immune-mediated diseases. This monoclonal antibody works by specifically inhibiting a important pathway involved in inflammation , offering a different approach compared to traditional therapies. Prel